75.98
0.36%
+0.27
After Hours:
75.98
Hologic, Inc. stock is currently priced at $75.98, with a 24-hour trading volume of 897.55K.
It has seen a +0.36% increased in the last 24 hours and a -0.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $76.02 pivot point. If it approaches the $75.08 support level, significant changes may occur.
Previous Close:
$75.71
Open:
$75.23
24h Volume:
897.55K
Market Cap:
$17.83B
Revenue:
$3.97B
Net Income/Loss:
$515.10M
P/E Ratio:
39.37
EPS:
1.93
Net Cash Flow:
$858.70M
1W Performance:
+0.80%
1M Performance:
-0.25%
6M Performance:
+15.49%
1Y Performance:
-9.10%
Hologic, Inc. Stock (HOLX) Company Profile
Name
Hologic, Inc.
Sector
Industry
Phone
508-263-2900
Address
250 Campus Drive, Marlborough, MA
Hologic, Inc. Stock (HOLX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-14-23 | Upgrade | Needham | Hold → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-13-22 | Initiated | Mizuho | Buy |
Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
Jul-20-22 | Initiated | UBS | Neutral |
Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
Oct-15-21 | Resumed | Cowen | Outperform |
Oct-14-21 | Initiated | Redburn | Neutral |
Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
Nov-20-20 | Downgrade | Needham | Buy → Hold |
Nov-05-20 | Reiterated | Needham | Buy |
Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Apr-30-20 | Reiterated | Needham | Buy |
Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jan-13-20 | Reiterated | Needham | Buy |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Buy |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Aug-01-19 | Reiterated | Needham | Buy |
May-02-19 | Reiterated | Needham | Buy |
Jan-31-19 | Reiterated | Needham | Buy |
Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Oct-09-18 | Initiated | UBS | Neutral |
Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic, Inc. Stock (HOLX) Latest News
3 Medical Products Stocks Set to Beat This Earnings Season
Zacks Investment Research
Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks Investment Research
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
Zacks Investment Research
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
Zacks Investment Research
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
Hologic, Inc. Stock (HOLX) Financials Data
Hologic, Inc. (HOLX) Revenue 2024
HOLX reported a revenue (TTM) of $3.97 billion for the quarter ending December 31, 2023, a -11.12% decline year-over-year.
Hologic, Inc. (HOLX) Net Income 2024
HOLX net income (TTM) was $515.10 million for the quarter ending December 31, 2023, a -47.98% decrease year-over-year.
Hologic, Inc. (HOLX) Cash Flow 2024
HOLX recorded a free cash flow (TTM) of $858.70 million for the quarter ending December 31, 2023, a -49.37% decrease year-over-year.
Hologic, Inc. (HOLX) Earnings per Share 2024
HOLX earnings per share (TTM) was $2.11 for the quarter ending December 31, 2023, a -46.17% decline year-over-year.
About Hologic, Inc.
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Cap:
|
Volume (24h):